SEC Form 4 · accession 0001127602-18-016658
CONMED Corp · CNMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark E Tryniski
Director
Period of report
May 7, 2018
Accepted (ET)
May 8, 2018 · 4:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 7, 2018 | M | 2,500 | $25.70 | A | 34,178 | D | |
| Common Stock | May 7, 2018 | F | 954 | $67.37 | D | 33,224 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sars (Stock Appreciation Rights)F1 | $25.70 | May 7, 2018 | M | 2,500 | D | — | May 16, 2018 | Common Stock | 2,500 | 0 | D |
Explanation of responses
- F1The stock appreciation rights ("SARs") were granted under the Company's 2007 Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 20% per year over a five year period, with any unvested SARs to vest upon the Director's termination of service provided the Director has completed one full year of service since the date of the award in which case the SARs shall be exercisable at any time prior to the expiration date of the SAR or within one year after the date of such termination, whichever period is shorter.